RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All MHRA (UK) updates
MHRA (UK)
OTHER
Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film, EL(25)A/47
Published: 11/10/2025Detected: 3/22/2026

Summary preview

Zambon SpA is recalling a batch of Emylif 50mg orodispersible film due to out of specification results linked to unknown impurities identified during stability testing.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
quality
safety
#recall
#quality control
#stability testing
#impurities
#pharmaceutical manufacturing

Official Source Document
Source Verified

Access the original document directly from MHRA.

View Official Document

More from MHRA (UK)

  • Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/4010/1/2026
  • Field Safety Notices: 21 to 25 September 20269/29/2026
  • MHRA Safety Roundup: September 20269/29/2026
  • Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/399/23/2026
  • Field Safety Notices: 14 to 18 September 20269/23/2026

Get MHRA (UK) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.